Nama's AI scorecard currently rates Travere Therapeutics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TVTX's P/E ratio?

Travere Therapeutics trades at a trailing price-to-earnings ratio of 4960.0.

When does TVTX report earnings?

Travere Therapeutics's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.84.

What is the TVTX price target?

The median analyst price target from 14 analysts is $75.50, with a range of $62.00 – $90.00.

Is TVTX Shariah compliant?

Nama's AAOIFI-style screen reads Travere Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Travere Therapeutics (TVTX)

Healthcare · Biotechnology · NASDAQ

Travere Therapeutics (TVTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.76B, a trailing price-to-earnings ratio of 4960.0 and a free-cash-flow yield of -0.5%. Over the most recent reported fiscal year, revenue grew 110.5%. Nama's AI scorecard rates it Sell, 3.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 3.5/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +60.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-27.8%

How far the last close sits under the highest price of the past five years.

Market cap	$4.76B
Trailing P/E	4960.0
Price / book	190.8
Price / sales	7.9
FCF yield	-0.5%
Dividend yield	—
Gross margin	93.2%
Operating margin	-6.8%
Net margin	-7.3%
Revenue growth (YoY)	+110.5%
Revenue growth (3-yr annual)	+64.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

TVTX earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate $0.84). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	-$0.31	$0.42	-173.8%	$224.56M
Q2 2026	Aug 4, 2026	-$0.10	$0.32	-131.2%	$169.58M
Q1 2026	May 4, 2026	$0.05	-$0.06	+183.3%	$127.20M
Q4 2025	Feb 19, 2026	$0.37	$0.37	+0.0%	$129.69M

TVTX analyst price target

Median target $75.50 from 14 analysts, ranging $62.00 – $90.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live TVTX data on Nama Insights →

TVTX FAQ

Is TVTX a buy?: Nama's AI scorecard currently rates Travere Therapeutics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TVTX's P/E ratio?: Travere Therapeutics trades at a trailing price-to-earnings ratio of 4960.0.
When does TVTX report earnings?: Travere Therapeutics's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.84.
What is the TVTX price target?: The median analyst price target from 14 analysts is $75.50, with a range of $62.00 – $90.00.
Is TVTX Shariah compliant?: Nama's AAOIFI-style screen reads Travere Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.